ABT PARTNERS WITH CDC ON NEJM STUDY SHOWING COVID-19

Rockville, MD, June 8, 2021 (GLOBE NEWSWIRE) – An upcoming New England Journal of Medicine Article on a study by the Centers for Disease Control and Prevention (CDC) shows that COVID-19 vaccines are highly effective in working-age adults in real-life conditions. Abt Associates worked with the CDC on the study, which showed that the vaccines not only prevent SARS-CoV-2 infections, but also reduce serious symptoms in people with breakthrough infections despite being vaccinated. The study was published in preprint via medRXiv.

This publication pools data from two CDC-funded studies: Research on the Epidemiology of SARS-CoV-2 in Essential Response Personnel (RECOVER), a study led by Abt, and Healthcare, Emergency Response, and Other Essential Workers Surveillance (HEROES). operated by the University of Arizona. A group of 3,975 health workers, first responders, and other key and frontline workers performed weekly SARS-CoV-2 nasal swab tests from December 14, 2020 to April 10, 2021. They were in eight locations, six of which are managed by the Abbot team at RECOVER: Tucson, Arizona; Miami, Florida; Duluth, Minnesota; Portland, Oregon; Temple, Texas; and Salt Lake City, Utah. The other two locations, which are in Arizona, are administered by the University of Arizona.

The results showed that the adjusted efficacy of the vaccine for full vaccination was 91% against symptomatic or asymptomatic SARS-CoV-2 infection. In the case of vaccination, the effectiveness rate was 81%. In addition, in partially or fully vaccinated participants with SARS-CoV-2 infection, the viral RNA load was significantly reduced compared to the load in unvaccinated study participants, as the data showed. That means there was less of the virus that caused COVID-19. Those who were vaccinated had a 58% lower risk of self-reported fever and spent 2.3 days less sick in bed than those who were not vaccinated.

“It is encouraging to see that vaccines used in the real world can effectively prevent the vast majority of COVID-19 infections – and also mitigate the effects of these ‘breakthrough’ infections when they occur,” said Lauren Olsho, the abbot lead investigator on the study and an abbot lead investigator.

Such studies “increase public knowledge and understanding of COVID-19,” adds project leader Danielle Hunt, vice president and senior epidemiologist at Abt. “The data we bring to the table can help create evidence-based guidelines.”

###

About Abt Associates

Abbot staff is a global consulting and research company that uses data and bold thinking to improve people’s quality of life. From fighting infectious diseases and conducting rigorous research and program evaluations, to ensuring clean drinking water and promoting access to affordable housing – and more – we work with customers and communities to address their most complex challenges.

http://abt.associates/cdcsolutions

        

Comments are closed.